Search

ObjectiveTo compare on-treatment efficacy and discontinuation outcomes in teriflunomide (TFL) and dimethyl fumarate (DMF) in the treatment of relapsing-remitting multiple sclerosis (RRMS) in a real-world setting.MethodsWe identified all patients starting TFL or DMF from the Danish Multiple Sclerosis Registry and compared on-treatment efficacy outcomes between DMF using TFL, adjusted for clinical baseline variables and propensity score-based methods.ResultsWe included 2,236 patients in the study: 1,469 patients on TFL and 767 on DMF. Annualized relapse rates (ARRs) in TFL and DMF were 0.16 (95% confidence interval [CI] 0.13–0.20) and 0.09 (95% CI 0.07–0.12), respectively. Relapse rate ratio for DMF/TFL was 0.58 (95% CI 0.46–0.73, p < 0.001). DMF had a higher relapse-free survival proportion at 48 months of follow-up (p < 0.05). We observed no difference in Expanded Disability Status Scale score worsening. Discontinuations due to disease breakthrough were 10.2% (95% CI 7.6%–12.8%) and 22.1% (95% CI 19.2%–25.0%) for DMF and TFL, respectively. A subgroup analysis of ARRs in 708 patients with available baseline MRI T2 lesion amount reported similar results after adjustment.ConclusionWe found lower ARR, higher relapse-free survival, and lower incidence of discontinuation due to disease breakthrough on treatment with DMF compared with TFL.Classification of evidenceThis study provides Class II evidence that for patients with RRMS, DMF is more effective in preventing relapses and has lower discontinuation due to disease breakthrough compared with TFL.

Objective Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013–2019. Methods This was a complete nationwide population-based cohort study with prospectively enrolled unselected cases. Demographic and disease-specific patient parameters related to treatment history, efficacy outcomes, and discontinuation and switching rates among other clinical variables were assessed at baseline and during follow-up visits. Results A total of 3239 patients (65.4% female) started treatment with teriflunomide during the study period, 56% of whom were treatment-naïve. Compared to previously treated patients, treatment-naïve patients were older on average at disease onset, had a shorter disease duration, a lower Expanded Disability Status Scale score at teriflunomide treatment start and more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off date, 72.7% were still on treatment one year after treatment start. Discontinuations in the first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5% of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated with teriflunomide for 5 years were relapse-free, while significantly more treatment-naïve versus previously treated patients experienced a relapse during the follow-up (p Conclusions Solid efficacy and treatment persistence data consistent with other real-world studies were obtained over the treatment period. Treatment outcomes in this real-world scenario of the population-based cohort support previous findings that teriflunomide is an effective and generally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity.

Dialkyl [2-hydroxy-5-(phenylazo)benzyl]phosphonates were prepared by a convenient procedure in good yield from Mannich base and trialkyl phosphite in benzene with the elimination of ammonium or morpholinium cation. 2-[(Dialkylamino)methyl]-4-(phenylazo)phenol methiodide is a new reagent in the Michaelis-Arbuzov reaction.

We present a new class of solvents containing nonfluorous, well-established, nontoxic organoanions that can be used as “green” alternatives to volatile organic solvents in a variety of applications such as solvent extraction, antielectrostatic agents, and as electrolytes in solar-cell applications. The acesulfamate anion is an effective substitute for very expensive bis(trifluoromethylsulfonyl)imide (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005)

The products of a reaction between 3-ethoxymethylpyridine and chloromethylalkyl ether or sulfide were proven to be 1 -[(alkylthio)- methyl]-3-[(ethoxy)methyl]pyridinium or 1 -[(alkoxy)methyl]-3-[(ethoxy)- methyl]pyridinium chlorides. Bacteriostatic properties of the obtained chlorides against 13 different microbial strains representing cocci, rods, fungi, and bacilli were studied. The MICs were measured by serial dilution. All studied chlorides showed bacteriostatic properties. Particularly high activity against microbes was shown by 1-[(dodecylthio)- methyl]-3-[(ethoxy)methyl]pyridinium and 3-[(ethoxy)methyl]-1-[(tetradecylthio)methyl]pyridinium chlorides.

Dialkyl [2-hydroxy-5-(phenylazo)benzyl]phosphonates were prepared by a convenient procedure in good yield from Mannich base and trialkyl phosphite in benzene with the elimination of ammonium or morpholinium cation. 2-[(Dialkylamino)methyl]-4-(phenylazo)phenol methiodide is a new reagent in the Michaelis-Arbuzov reaction.

Yarrow, Achillea millefolium L., is one of the commonest weeds of the Compositae family. Cases of allergic contact dermatitis have been described since 1899. Although 10 sesquiterpene lactones (SL) and 3 polyines have previously been identified, the sensitizers of yarrow have escaped detection. A reinvestigation of short ether extracts of yarrow revealed the presence of 5 unsaturated hitherto unknown guaianolides of peroxide character. The main SL, identified as a strong sensitizer in guinea pig sensitization experiments, was named alpha-peroxyachifolid. The minor SL also contribute marginally to the sensitizing capacity, while other known yarrow constituents like dehydromatricaria ester and pontica epoxide appear to play no role. A 5-year follow-up (1985-1990) of Compositae-sensitive patients showed that more than 50% reacted when tested with a short ether extract of yarrow. Exacerbation of the patch test sites by irradiation with UV light was never observed.